Cardiovascular medication use following percutaneous coronary intervention: the Australian experience

Autoria(s): Cole,JA; Brennan,AL; Ajani,AE; Yan,BP; Duffy,SJ; Loane,P; Reid,CM; Yudi,MB; New,G; Black,A; Shaw,J; Clark,DJ; Andrianopoulos,N
Data(s)

01/04/2014
Resumo

Despite the guidelines, a "treatment gap" exists in the delivery of pharmacotherapy for secondary prevention. We aimed to analyze the trend in guideline-based medication usage following percutaneous coronary intervention (PCI) using the Melbourne Interventional Group (MIG) registry over a 6-year period (2005-2010).
Identificador

http://hdl.handle.net/10536/DRO/DU:30072021
Idioma(s)

eng
Publicador

Wiley-Blackwell Publishing
Relação

http://dro.deakin.edu.au/eserv/DU:30072021/black-cardiovascularmedication-2014.pdf

http://www.dx.doi.org/10.1111/1755-5922.12060

http://www.ncbi.nlm.nih.gov/pubmed/24393169
Direitos

2014, Wiley-Blackwell Publishing
Palavras-Chave #Guidelines #Medications #Percutaneous coronary intervention #Registry
Tipo

Journal Article
Acesso ao item digital